(Q34725758)

4 August 2017

1 reference

title

Antibody-based immunotherapy in high-risk neuroblastoma (English)

1 reference

4 August 2017

1 reference

1 reference

Erik Johnson

1

1 reference

4 August 2017

Shannon M Dean

series ordinal

2

1 reference

4 August 2017

Paul M Sondel

series ordinal

3

1 reference

4 August 2017

publication date

17 December 2007

1 reference

Expert Reviews in Molecular Medicine

4 August 2017

published in

1 reference

4 August 2017

volume

9

1 reference

4 August 2017

issue

34

1 reference

4 August 2017

page(s)

1-21

1 reference

Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Human T lymphocyte genetic modification with naked DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Genetic modification of T lymphocytes for adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Early Molecular Response of Marrow Disease to Biologic Therapy Is Highly Prognostic in Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Monoclonal antibody-based therapy for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Mechanisms of ganglioside inhibition of APC function

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Immune evasion of tumor cells using membrane-bound complement regulatory proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and az

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

FcgammaR: The key to optimize therapeutic antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Humanization of Predicted T-Cell Epitopes Reduces the Immunogenicity of Chimeric Antibodies: New Evidence Supporting a Simple Method

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Antibody-directed, effector cell-mediated tumor destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Monoclonal antibody-based therapy of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

What does it take to make a natural killer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Evaluation of radioiodinated and radiocopper labeled monovalent fragments of monoclonal antibody chCE7 for targeting of neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Immunolocalization of neuroblastoma using radiolabeled monoclonal antibody UJ13A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Effective targeted cytotoxicity of neuroblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Immunocytokines: a promising approach to cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Neuroblastoma in adults and adolescents: an indolent course with poor survival

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Generation of a humanised single chain Fv (Scfv) derived from the monoclonal Eric-1 recognising the human neural cell adhesion molecule

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8.

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord

1 reference

https://api.crossref.org/works/10.1017%2FS1462399407000518

7 January 2021

10.1017/S1462399407000518

Identifiers

DOI

0 references

1 reference